Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

– Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience – – Served as Neuroimmunology Franchise Head Responsible for Roche's Blockbuster Launch of Multiple Sclerosis Therapy Ocrevus® – NEW YORK , July 24, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX ) , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the appointment of Simona Skerjanec , M.Pharm, MBA, a thought-leader in brain health with decades of experience in drug development and commercialization, to its board of directors, effective July 22, 2024 .

Over a nearly three-decade career in the United States and internationally, Ms. Skerjanec has led research and development efforts culminating in numerous regulatory drug approvals and successful commercial launches. Most recently, Ms.

Skerjanec served as Senior Vice President, Global Head Neuroscience and Rare Diseases at Roche. In this role, she led business and global corporate strategy for Roche's portfolio of neurological and rare diseases, achieving sustainable double digit growth in sales, including with Ocrevus® (ocrelizumab)*, which remains one of the most successful medicines for the treatment of multiple sclerosis (MS). Earlier at Roche, Ms.

Skerjanec served as Neuroimmunology Franchise Head, responsible for the commercial launch of Ocrevus®, generating over $1 billion in.